

Instructions for use

Preservative free ophthalmic solution

Read the whole leaflet carefully

before you start using this product. Keep this leaflet; you may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

If symptoms persist or you have any side effects please consult your doctor.

What is Ocutears[®] Hydro+ and what it is used for?

Ocutears® Hydro+ is a lubricating ophthalmic solution, based on high concentrated cross-linked sodium hyaluronate (0.4%), formulated for the relief of dry eye symptoms, even in severe cases, ocular discomfort and corneal protection.

This product is sterile and preservative free.

Cross-linked sodium hyaluronate gives the product a high viscoelasticity ensuring a high degree of hydration and permanence on the ocular surface, providing long lasting relief from dry eye symptoms, such as soreness, burning, stinging, sandy or gritty sensation, tired heavy or watery eyes.

Ocutears® Hydro+ is indicated:

- for the relief of dry eye symptoms, ocular discomfort and also for corneal protection as a tear substitute, providing lasting hydration.
- can be administered for ocular lubrication even when using contact lenses

Ocutears® Hydro+ is useful during and after:

- prolonged exposure to sunlight;
- exposure to air-conditioned rooms;
- prolonged screen use;
- contact with cleansing agents;
- Ocutears® Hydro+ could also relieve the post surgery discomfort of the eye.


How to use Ocutears® Hydro+

Administer 1 or 2 drops in each eye one or more times a day or as advised by your doctor or pharmacist.

Wash your hands before opening the container and pay attention to hygiene during handling.

Bottle:

 Before first opening pull and remove the tamper evident band completely.









3) Close firmly the bottle after use.

UD:

1) Take the strip of minicontainers and remove one.



OCUTEARS OCUTEARS OCUTEARS OCUTEARS OCUTEARS OCUTEARS

Open the container by twisting the cap.

3) Gently squeeze 1 drop into the eye.

4) Discard properly the remaining product in the minicontainer after use.

Warnings:

- Do not use the product if allergic or hypersensitive to any of the components;
- Use the bottle within 90 days from opening; the single dose container should be used immediately after opening and discarded after use;
- Do not use the product after the expiry date indicated on the pack;
- Do not use the product if the packaging is damaged;
- Keep away from heat, sunlight, moisture and the reach of children;
- Do not ingest;
- Take care that the tip of the container does not come into contact with the eye;
- Store the product below 25°C. Do not freeze:

Composition:

Cross-linked sodium hyaluronate 0.4%, Disodium tetraborate decahydrate, Boric acid, Sodium chloride, Water for injections (WFI).

Presentations:

10 ml bottle (PFMD), 0.35 ml x 15 UD, 0.35 ml x 5 UD (sample), 0.35 ml x 2 UD (sample)

For further information please contact your doctor or your local Santen Office at www.santen.eu

OFFHEALTH S.p.A., Via Giovanni Paisiello 10,



Italy

50144 Florence,

This leaflet was revised in September 2022

~~		-25°C	*	STERILE A	LOT
Manufacturing date	Manufacturer	Store below 25°C	Keep away from sunlight	Sterilized using aseptic processing techniques	Batch code
	Ĩ	\otimes		Ť	MD
Use by date	Consult instructions for use	Do not re-use	Do not use if package is damaged	Keep dry	Medical device
			·		019485

	MARVACO OY SAVIPAJAKATU 10, FIN-28610 PORI, FINLAND santen@marvaco.fi marvaco.fi • marvaco.se			14.02.2023 Proof No. 5	Santen
Part No: CAW-5708-01 Leaflet Ocutears Hydro+ Item No: 019482	Dimensions: 130x360 mm Fonts/Size: Helvetica Neue 9-16 pt	Country: IE, UK Component code: 019485	Colors:	Black	Technical PLEASE, CHECK THE SPOT COLORS FROM PANTONE [®] COLOR GUIDE.

Username	Full Name	Status	Date/Time (UTC)	
Johannalmmonen	Johanna Immonen	Approved	15-Feb-2023 08-52 UTC	
KatalinDebrei	Katalin Debrei	Approved	15-Feb-2023 09-14 UTC	
LuciaSumma	Lucia Summa	Approved	16-Feb-2023 09-16 UTC	
AnneSilventoinen	Anne Silventoinen	Approved	16-Feb-2023 10-31 UTC	
IndreBidlauskaite Indre Bidlauskaite		Approved	16-Feb-2023 14-14 UTC	